Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Laron Syndrome

ClinicalTrials.gov lists 2 trials for Laron Syndrome or a narrower condition beneath it.

MeSH D046150 Musculoskeletal Diseases C05 C16 C19 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Trials started per year Trials started per year 1 Trials by phase Trials by phase 1 Trials by recruitment status Trials by recruitment status 1 Lead sponsors Lead sponsors 2 Serious adverse events in this condition's trials Serious adverse events in this condition's trials 10 Publications Publications 4 Prevalence Prevalence 6 Rare-disease identity Rare-disease identity 2 Trials started per year Trials started per year 1 Trials by phase Trials by phase 1 Trials by recruitment status Trials by recruitment status 1 Lead sponsors Lead sponsors 2 Serious adverse events in this condition's trials Serious adverse events in this condition's trials 10 Publications Publications 4 Prevalence Prevalence 6 Rare-disease identity Rare-disease identity 2

Rows recorded per section

1 section measured, none recorded · 1 not measured yet · 1 not computed

2 of the 2 trials are tagged with Laron Syndrome itself; the rest are tagged with a narrower condition beneath it.

Get the Laron Syndrome report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Laron Syndrome trials start? (1)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials started per year
Year Trials started
1991 1

No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Laron Syndrome trials in? (1)

Shown in this order: phase order.

Trials by phase
Phase Trials
Phase 2/3 2

How many Laron Syndrome trials are recruiting? (1)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Completed 2

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Laron Syndrome trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Insmed Incorporated 1
Ipsen 1

Which serious adverse events do Laron Syndrome trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Adenoidal hypertrophy 3 1
Appendicitis 2 1
Tonsillar hypertrophy 2 1
Abdominal pain 1 1
Benign intracranial hypertension 1 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Laron Syndrome? (4)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry. The Journal of clinical endocrinology and metabolism 2023 Yes
Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome. European journal of endocrinology 2021 Yes
GH deficiency in adult B-thalassemia major patients and its relationship with IGF-1 production. Pediatric endocrinology reviews : PER 2011 Yes
Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. The Journal of clinical endocrinology and metabolism 2007 Yes

Prevalence (6)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Laron syndrome Point prevalence 1-9 / 100 000 China Not stated Exact
Laron syndrome Point prevalence 1-9 / 100 000 China Not stated Exact
Laron syndrome Point prevalence 1-9 / 1 000 000 Europe Not stated Unspecified
Laron syndrome Point prevalence 1-9 / 1 000 000 Europe Not stated Exact
Laron syndrome Point prevalence 1-9 / 1 000 000 Europe Not stated Exact

Showing 5 of 6 prevalence observations.

Start your 14-day trial Email me all 6 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Laron syndrome 633 Exact Orphanet Rare Disease Ontology (ORDO)
Laron syndrome 633 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Not computed for conditions with fewer than 10 trials: drugs tested.

Browse all condition evidence pages